AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$CYRX

Cryoport (CYRX) Q3 2026 Earnings Call Transcript

Cryoport (CYRX) reported Q3 2026 revenue of $50.2M, up 14% YoY, with life sciences services growing 18%. The company raised its full-year revenue outlook to $197M-$199M. Cryoport supports 23 commercial therapies and has a record 788 clinical trials, with 2 potential new therapy approvals expected in Q4. The company achieved ISO certifications and received industry awards.

Original reporting
finance.yahoo.com
Published Nov 6, 2026, 8:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 8:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Cryoport (CYRX) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$CYRXBullishMed
01

Why it matters

The guidance raise is the primary catalyst for short‑term price movement.

02

Market read

First report of updated revenue guidance for a small‑cap biotech logistics firm; modest but actionable for traders.

03

What to watch

Potential headwinds from macro‑economic slowdown and foreign exchange exposure in Europe.

Relevance 6/10Novelty 7/10Timing: post‑earnings today

Background

Cryoport's Q3 2026 earnings call highlighted 14% YoY revenue growth, positive adjusted EBITDA, and a raised full‑year revenue outlook.

Company-level read

Ticker impact

$CYRXBullishHigh confidence
Context

Cryoport raised its full‑year 2026 revenue outlook to $197‑199 million after reporting Q3 results.

Expected impact

upward pressure as investors price in higher revenue expectations

Evidence & confidence

The new revenue range exceeds prior guidance and follows a beat on Q3 revenue, indicating momentum.

Market effects

Sector

Positive signal for the life‑sciences logistics and cryogenic storage sector.

Regional

May boost other US‑listed biotech logistics firms.

Global

Limited to niche supply‑chain players; no broad market effect.

Counterpoint

What could challenge this read

Guidance could be premature if upcoming FDA approvals face delays.

Key entities

  • Executive
    Jerrell W. Shelton

    CEO of Cryoport

  • Executive
    Robert S. Stefanovich

    CFO of Cryoport

Read at source← All news

Related articles

$CYRXMed

CryoPort Q3 Earnings Call Highlights

CryoPort reported Q3 supporting 23 commercial therapies and 788 clinical trials. China operations contribute 3-4% of revenue. The company expects five regulatory filings and two potential new therapy approvals in 2026. Guidance is conservative, focusing on existing clients. Expansion plans include new BioServices capabilities in Paris and California, with long-term margin goals of 55% gross and 30% adjusted EBITDA.

finance.yahoo.com
$CYRXMed

Cryoport Reports Third Quarter 2026 Financial Results

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Third Quarter 2026 Financial Results · Third quarter revenue grew 14% year-over-year to $50.2 million · Commercial Cell and Gene Therapy revenue increased 20% year-over-year · Supporting a record 788 global clinical trials and 23 commercially approve

SEC EDGAR 8-K
$CYRXMedAI 8/10

Cryoport (CYRX) Q2 2026 Earnings Call Transcript

Cryoport (CYRX) reported Q2 2026 revenue of $49 million, up from prior periods, led by Life Science Services. Life Science Services revenue rose 15% year over year, with biostorage and bioservices up 25%. Support for commercial cell and gene therapy rose 9% to $9.4 million. Adjusted EBITDA turned positive at $0.4 million. Full-year 2026 revenue guidance remains $192 million to $196 million.

yahoo.com
$CYRXMed

Cryoport Reports Second Quarter 2026 Financial Results

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Second Quarter 2026 Financial Results · Second quarter revenue grew 8% year-over-year to $49.0 million · Life Sciences Services revenue increased 15% year-over-year · BioStorage/BioServices revenue grew 25% year-over-year · Supporting 779 global clin

SEC EDGAR 8-K
$RVMDMedAI 8/10

Why is Revolution Medicines stock surging today?

Revolution Medicines (RVMD) stock rose 7% after reporting Q3 revenue of $197.6M, exceeding estimates, driven by its new drug RASONQUE. Analysts raised price targets, with HC Wainwright setting a $350 target. The company has strong cash reserves and reaffirmed its 2026 expense guidance. NASDAQ and S&P 500 gains provided a supportive market backdrop.

investing.com
HighAI 9/10

Why is Ubiquiti stock surging today?

Ubiquiti's stock rose 16.9% after reporting fiscal Q1 2027 results. Revenue was $1.026 billion, beating estimates, with GAAP EPS of $5.29. The Enterprise Technology segment drove growth. The company declared a $1.00 dividend. Analysts have mixed views, with a consensus price target of $734.50. The broader market also gained.

investing.com